EP4218748A3 - Bmp-mimetika - Google Patents

Bmp-mimetika Download PDF

Info

Publication number
EP4218748A3
EP4218748A3 EP23152770.6A EP23152770A EP4218748A3 EP 4218748 A3 EP4218748 A3 EP 4218748A3 EP 23152770 A EP23152770 A EP 23152770A EP 4218748 A3 EP4218748 A3 EP 4218748A3
Authority
EP
European Patent Office
Prior art keywords
bmp
mimetics
interest
compound
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23152770.6A
Other languages
English (en)
French (fr)
Other versions
EP4218748A2 (de
Inventor
Prof. Dr. Dennis Schade
Dr. Jonas Halver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Christian Albrechts Universitaet Kiel
Original Assignee
Christian Albrechts Universitaet Kiel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christian Albrechts Universitaet Kiel filed Critical Christian Albrechts Universitaet Kiel
Publication of EP4218748A2 publication Critical patent/EP4218748A2/de
Publication of EP4218748A3 publication Critical patent/EP4218748A3/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP23152770.6A 2017-09-01 2018-08-24 Bmp-mimetika Pending EP4218748A3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17189054.4A EP3449918A1 (de) 2017-09-01 2017-09-01 Bmp-mimetik
EP18758625.0A EP3675844B1 (de) 2017-09-01 2018-08-24 Bmp-mimetik
PCT/EP2018/072884 WO2019042889A1 (en) 2017-09-01 2018-08-24 MIMETICS OF BMP

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP18758625.0A Division EP3675844B1 (de) 2017-09-01 2018-08-24 Bmp-mimetik
EP18758625.0A Division-Into EP3675844B1 (de) 2017-09-01 2018-08-24 Bmp-mimetik

Publications (2)

Publication Number Publication Date
EP4218748A2 EP4218748A2 (de) 2023-08-02
EP4218748A3 true EP4218748A3 (de) 2023-08-16

Family

ID=59761853

Family Applications (3)

Application Number Title Priority Date Filing Date
EP17189054.4A Withdrawn EP3449918A1 (de) 2017-09-01 2017-09-01 Bmp-mimetik
EP18758625.0A Active EP3675844B1 (de) 2017-09-01 2018-08-24 Bmp-mimetik
EP23152770.6A Pending EP4218748A3 (de) 2017-09-01 2018-08-24 Bmp-mimetika

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP17189054.4A Withdrawn EP3449918A1 (de) 2017-09-01 2017-09-01 Bmp-mimetik
EP18758625.0A Active EP3675844B1 (de) 2017-09-01 2018-08-24 Bmp-mimetik

Country Status (3)

Country Link
EP (3) EP3449918A1 (de)
DK (1) DK3675844T3 (de)
WO (1) WO2019042889A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6832430B2 (ja) 2016-08-31 2021-02-24 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞代謝過程の阻害剤
JP7696354B2 (ja) 2019-10-21 2025-06-20 アライリオン インコーポレイテッド 睡眠障害の治療のためのＨ１および５－ＨＴ２Ａ受容体調節物質としての３－（４－（１１Ｈ－ジベンゾ［ｂ，ｅ］［１，４］アゼピン－６－イル）ピペラジン－１－イル）－プロパン酸誘導体および３－（４－（ジベンゾ［ｂ，ｆ］［１，４］オキサゼピン／チアゼピン／ジアゼピン－１１－イル）ピペラジン－１－イル）－プロパン酸誘導体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US7829332B2 (en) * 2004-02-13 2010-11-09 Cornell Research Foundation, Inc. Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JAMIE R. GENTHE ET AL: "Ventromorphins: A New Class of Small Molecule Activators of the Canonical BMP Signaling Pathway", ACS CHEMICAL BIOLOGY, vol. 12, no. 9, 29 August 2017 (2017-08-29), US, pages 2436 - 2447, XP055452348, ISSN: 1554-8929, DOI: 10.1021/acschembio.7b00527 *
LEPPARANTA OUTI ET AL: "Bone Morphogenetic Protein-Inducer Tilorone Identified by High-Throughput Screening Is Antifibrotic In Vivo", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 48, no. 4, April 2013 (2013-04-01), pages 448 - 455, XP093062898, ISSN: 1044-1549 *
TAKAYUKI YONEZAWA ET AL: "Harmine promotes osteoblast differentiation through bone morphogenetic protein signaling", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 409, no. 2, 2011, pages 260 - 265, XP028375635, ISSN: 0006-291X, [retrieved on 20110506], DOI: 10.1016/J.BBRC.2011.05.001 *
VRIJENS: "Identification of Small Molecule Activators of BMP Signaling", PLOS ONE 8(3): E59045, 19 March 2013 (2013-03-19), XP055452356, Retrieved from the Internet <URL:http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0059045&type=printable> [retrieved on 20180219] *
WU XU ET AL: "A small molecule with osteogenesis-inducing activity in multipotent mesenchymal progenitor cells", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, US, vol. 124, no. 49, 1 January 2002 (2002-01-01), pages 14520 - 14521, XP003005264, ISSN: 0002-7863, DOI: 10.1021/JA0283908 *
YAMASAKI ATSUSHI ET AL: "Identification of the role of bone morphogenetic protein (BMP) and transforming growth factor-beta (TGF-beta) signaling in the trajectory of serotonergic differentiation in a rapid assay in mouse embryonic stem cells in vitro", JOURNAL OF NEUROCHEMISTRY, vol. 132, no. 4, February 2015 (2015-02-01), pages 418 - 428, XP093062857, ISSN: 0022-3042 *

Also Published As

Publication number Publication date
WO2019042889A1 (en) 2019-03-07
EP3675844A1 (de) 2020-07-08
EP4218748A2 (de) 2023-08-02
EP3449918A1 (de) 2019-03-06
DK3675844T3 (da) 2023-06-19
EP3675844B1 (de) 2023-03-08

Similar Documents

Publication Publication Date Title
EP3600031A4 (de) Robotische systeme zur navigation von luminalen netzwerken, die physiologisches rauschen ausgleichen
PH12021553018A1 (en) New egfr inhibitors
AU2018338314A1 (en) Protein degraders and uses thereof
MX2018005292A (es) Inhibidores de acc y usos de los mismos.
EP4279071A3 (de) Neuartige cannabinoidformulierungen
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
PL3941224T3 (pl) Układ zastępujący palenie
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
PL3711510T3 (pl) Układ zastępujący palenie
EP4302827A3 (de) Rapamycinanaloga und verwendungen davon
PL3941227T3 (pl) System zastępujący palenie
MX2025010903A (es) Compuestos polimorficos y usos de los mismos
PH12019550221A1 (en) Method for producing dual function proteins and its derivatives
PL3711552T3 (pl) Układ zastępujący palenie
PL3941250T3 (pl) System zastępujący palenie
CA190044S (en) Portion of an insole
PL3941256T3 (pl) Układ zastępujący palenie
EP4218748A3 (de) Bmp-mimetika
PL3941251T3 (pl) System zastępujący palenie
CA190047S (en) Portion of an insole
PH12019501977B1 (en) Additive composition for ground improvement
PL3941234T3 (pl) Układ zastępujący palenie
HUE067628T2 (hu) Dohányzást helyettesítõ rendszer
MX2020012016A (es) Sistemas y metodos para cuantificar y modificar la viscosidad de proteinas.
EP3628681A4 (de) Verfahren zur verlängerung der halbwertszeit von protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AC Divisional application: reference to earlier application

Ref document number: 3675844

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/10 20060101ALI20230713BHEP

Ipc: A61K 31/553 20060101ALI20230713BHEP

Ipc: A61K 31/5415 20060101ALI20230713BHEP

Ipc: A61K 31/519 20060101ALI20230713BHEP

Ipc: A61K 31/495 20060101ALI20230713BHEP

Ipc: A61K 31/454 20060101ALI20230713BHEP

Ipc: A61K 31/445 20060101ALI20230713BHEP

Ipc: A61K 31/404 20060101ALI20230713BHEP

Ipc: A61K 31/352 20060101ALI20230713BHEP

Ipc: A61K 31/155 20060101ALI20230713BHEP

Ipc: A61K 31/14 20060101AFI20230713BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240212

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250804